SMARCA4 and mantle cell lymphoma: Specifically, in MCL, an upregulation of the pro-survival gene BCL2L1 (Bcl-xL) has been observed when SMARCA4 harbors loss-of-function mutations, which results in primary resistance to ibrutinib and venetoclax treatments or, eventually, in relapse after dual exposure to these agents [232].